Candriam S.C.A. Takes Position in Celldex Therapeutics, Inc. $CLDX

Candriam S.C.A. purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the first quarter, Holdings Channel.com reports. The institutional investor purchased 278,888 shares of the biopharmaceutical company’s stock, valued at approximately $8,846,000.

Several other large investors have also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the last quarter. Millennium Management LLC lifted its holdings in Celldex Therapeutics by 327.3% in the 1st quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company’s stock valued at $7,259,000 after purchasing an additional 306,330 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Celldex Therapeutics by 12.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company’s stock worth $2,383,000 after buying an additional 14,979 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Celldex Therapeutics in the second quarter valued at about $347,000.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $39.11 on Monday. Celldex Therapeutics, Inc. has a 52-week low of $19.72 and a 52-week high of $40.30. The stock has a fifty day simple moving average of $32.98 and a two-hundred day simple moving average of $30.04. The company has a market capitalization of $3.07 billion, a PE ratio of -9.18 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, equities analysts anticipate that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on CLDX. Wolfe Research raised shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a research note on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $42.00 price objective on shares of Celldex Therapeutics in a report on Monday, June 15th. Barclays raised their target price on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, UBS Group boosted their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Celldex Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $49.30.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.